Gosset Angiotensinogen mRNA Overview
Angiotensinogen mRNA is the messenger RNA produced from the angiotensinogen (AGT) gene, which encodes the angiotensinogen protein—a precursor to angiotensin peptides. Angiotensinogen mRNA itself is not a drug target, receptor, enzyme, transporter, or protein, but its expression levels are studied in relation to regulation of angiotensinogen synthesis in tissues such as the liver and kidney[4]. The manipulation or measurement of angiotensinogen mRNA is primarily relevant in experimental settings to understand gene expression responses in hypertension and tissue-specific angiotensinogen production[4][5]. The canonical therapeutic target for angiotensin-related pathways is typically the angiotensinogen protein (AGT) or downstream receptors (e.g., the angiotensin II type 1 receptor, AT1R), not the mRNA itself[8][1]. For structured drug target annotations, selecting “angiotensinogen” (AGT) is scientifically accurate; the mRNA is not considered a true therapeutic target. If you intend to annotate a drug target, use "Angiotensinogen" (AGT), not "Angiotensinogen mRNA". Angiotensinogen is a glycoprotein precursor to all angiotensin peptides and is a member of the non-inhibitory serpin superfamily[3][5][8]. Regulated expression of angiotensinogen mRNA is key to homeostatic control of local and systemic Renin-Angiotensin-Aldosterone System (RAAS) activity, with roles in blood pressure regulation, sodium homeostasis, and cardiovascular pathophysiology[3][4]. Pathological increases in angiotensinogen mRNA precede excess angiotensin II formation implicated in hypertension and cardiovascular disease[4]. AGT is not itself a receptor, enzyme, or transporter, but is sometimes targeted by antisense oligonucleotides or RNAi experimentally to reduce protein levels and downstream angiotensin production[3][4]. Angiotensinogen mRNA is not a canonical therapeutic target. The protein product, "angiotensinogen," may be annotated as a target, but the mRNA transcript should not. Enter "Angiotensinogen" (AGT), not "Angiotensinogen mRNA," for structured target databases[8][3][4].
Mechanism of Action
Biological Functions
Disease Associations
Safety Considerations
No safety concerns listed